Evaxion A/S (EVAX) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
LeonaBio (LONA) has outperformed Evaxion A/S (EVAX) over the past year, losing 56.1% versus a loss of 56.6%. Over five years, LONA leads with a -98.6% price change compared with -99.1% for EVAX. LeonaBio is the larger company by market cap ($26.4 million vs $20.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | LONA |
|---|---|---|
| Share price | $2.25 | $2.02 |
| Market cap | $20.75M | $26.41M |
| 1-day change | +10.84% | -17.89% |
| YTD return | -52.83% | -73.32% |
| 1-year return | -56.56% | -56.13% |
| 5-year return | -99.07% | -98.55% |
| EPS (TTM) | $-1.00 | $-22.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.53M | — |
| Revenue growth (YoY) | +125.12% | — |
| Net income (latest FY) | $-7.71M | $-105.61M |
| Operating margin | -122.66% | — |
| Net margin | -102.38% | — |
| 52-week high | $6.92 | $14.21 |
| 52-week low | $2.03 | $1.91 |
| Distance from 52-week high | -67.49% | -85.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +400.00% | +757.92% |
| Average volume | 85.00K | 195.37K |
| Shares outstanding | 9.22M | 13.08M |
| Employees | 46 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
EVAX vs LONA FAQ
Which is bigger, Evaxion A/S or LeonaBio?
LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $20.75M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or LONA?
LONA returned -56.13% over the past 12 months, compared with -56.56% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.